The best metric is not weight, but a particularly toxic kind of fat.

Injected weight-loss drugs Wegovy, from Novo Nordisk, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a month.

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

WBZ-TV's Dr. Mallika Marshall reports that drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...